Revance Therapeutics, Inc. Announces Resignation of Caryn McDowell from Senior Vice President, General Counsel and Corporate Secretary
January 09, 2020 at 08:07 am
Share
On January 8, 2020, Caryn McDowell resigned as the Senior Vice President, General Counsel and Corporate Secretary of the Revance Therapeutics, Inc., with an anticipated effective date on or before March 31, 2020. Her departure is not based on any disagreement with the Company relating to its operations, policies or practices. In connection with Ms. McDowell’s resignation, the Company entered into a separation agreement (the “Separation Agreement”) with Ms. McDowell on January 8, 2020 providing for (i) a release of claims against the Company, (ii) cash severance payments to Ms. McDowell in an amount equal to nine months of her base salary, paid in equal installments on the Company’s regular payroll schedule over the nine month period following the separation date; and (iii) certain health care continuation benefits. The Separation Agreement also provides for an extension of the post-termination exercise period for all vested stock options held by Ms. McDowell through the earlier of a change in control or January 31, 2021.
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.